News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
374,956 Results
Type
Article (24680)
Company Profile (34)
Press Release (350242)
Multimedia
Podcasts (86)
Webinars (9)
Section
Business (121962)
Career Advice (1455)
Deals (17723)
Drug Delivery (65)
Drug Development (43679)
Employer Resources (99)
FDA (8914)
Job Trends (8673)
News (194800)
Policy (17595)
Tag
Academia (1489)
Academic (1)
Accelerated approval (4)
Adcomms (13)
Allergies (54)
Alliances (33775)
ALS (64)
Alzheimer's disease (846)
Antibody-drug conjugate (ADC) (107)
Approvals (8941)
Artificial intelligence (192)
Autoimmune disease (16)
Automation (15)
Bankruptcy (160)
Best Places to Work (7191)
BIOSECURE Act (12)
Biosimilars (54)
Biotechnology (26)
Bladder cancer (68)
Brain cancer (19)
Breast cancer (236)
Cancer (1819)
Cardiovascular disease (133)
Career advice (1238)
Career pathing (24)
CAR-T (93)
CDC (20)
Cell therapy (308)
Cervical cancer (15)
Clinical research (35832)
Collaboration (716)
Company closure (1)
Compensation (142)
Complete response letters (12)
COVID-19 (1533)
CRISPR (40)
C-suite (153)
Cystic fibrosis (61)
Data (1881)
Decentralized trials (2)
Denatured (26)
Depression (30)
Diabetes (207)
Diagnostics (3456)
Digital health (12)
Diversity (3)
Diversity, equity & inclusion (30)
Drug discovery (80)
Drug pricing (78)
Drug shortages (20)
Duchenne muscular dystrophy (77)
Earnings (56218)
Editorial (34)
Employer branding (14)
Employer resources (87)
Events (55849)
Executive appointments (470)
FDA (9874)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (6)
Funding (488)
Gene editing (79)
Generative AI (19)
Gene therapy (253)
GLP-1 (465)
Government (2429)
Grass and pollen (4)
Guidances (151)
Healthcare (10342)
Huntington's disease (15)
IgA nephropathy (23)
Immunology and inflammation (90)
Immuno-oncology (6)
Indications (24)
Infectious disease (1616)
Inflammatory bowel disease (100)
Inflation Reduction Act (9)
Influenza (29)
Intellectual property (74)
Interviews (269)
IPO (8470)
IRA (34)
Job creations (1830)
Job search strategy (1025)
Kidney cancer (9)
Labor market (28)
Layoffs (256)
Leadership (18)
Legal (4509)
Liver cancer (40)
Lung cancer (286)
Lymphoma (127)
Machine learning (4)
Management (34)
Manufacturing (229)
MASH (59)
Medical device (6717)
Medtech (6721)
Mergers & acquisitions (9682)
Metabolic disorders (502)
Multiple sclerosis (66)
NASH (9)
Neurodegenerative disease (63)
Neuropsychiatric disorders (17)
Neuroscience (1225)
NextGen: Class of 2025 (3480)
Non-profit (2711)
Now hiring (6)
Obesity (245)
Opinion (174)
Ovarian cancer (54)
Pain (59)
Pancreatic cancer (61)
Parkinson's disease (95)
Partnered (12)
Patents (171)
Patient recruitment (76)
Peanut (25)
People (29046)
Pharmaceutical (10)
Pharmacy benefit managers (10)
Phase I (10731)
Phase II (15302)
Phase III (12847)
Pipeline (1241)
Policy (127)
Postmarket research (1690)
Preclinical (4667)
Press Release (31)
Prostate cancer (110)
Psychedelics (18)
Radiopharmaceuticals (159)
Rare diseases (271)
Real estate (2635)
Recruiting (38)
Regulatory (12037)
Reports (25)
Research institute (1357)
Resumes & cover letters (222)
Rett syndrome (6)
RNA editing (4)
RSV (30)
Schizophrenia (49)
Series A (87)
Series B (49)
Service/supplier (3)
Sickle cell disease (40)
Special edition (12)
Spinal muscular atrophy (70)
Sponsored (18)
Startups (1605)
State (1)
Stomach cancer (13)
Supply chain (37)
Tariffs (37)
The Weekly (58)
Vaccines (498)
Venture capitalists (24)
Weight loss (144)
Women's health (23)
Worklife (14)
Date
Today (2)
Last 7 days (309)
Last 30 days (1400)
Last 365 days (19369)
2025 (9423)
2024 (20670)
2023 (22753)
2022 (29304)
2021 (31033)
2020 (30170)
2019 (25778)
2018 (19048)
2017 (18060)
2016 (17472)
2015 (19906)
2014 (16595)
2013 (14521)
2012 (14385)
2011 (13849)
2010 (13074)
Location
Africa (563)
Alabama (43)
Alaska (5)
Arizona (92)
Arkansas (7)
Asia (21830)
Australia (3672)
California (4084)
Canada (1341)
China (393)
Colorado (200)
Connecticut (211)
Delaware (110)
Europe (51845)
Florida (719)
Georgia (151)
Idaho (21)
Illinois (335)
India (19)
Indiana (228)
Iowa (4)
Japan (152)
Kansas (60)
Kentucky (10)
Louisiana (6)
Maine (27)
Maryland (560)
Massachusetts (3130)
Michigan (136)
Minnesota (194)
Mississippi (1)
Missouri (34)
Montana (9)
Nebraska (9)
Nevada (46)
New Hampshire (31)
New Jersey (1364)
New Mexico (12)
New York (1222)
North Carolina (657)
North Dakota (5)
Northern California (1811)
Ohio (119)
Oklahoma (12)
Oregon (20)
Pennsylvania (944)
Puerto Rico (2)
Rhode Island (23)
South America (771)
South Carolina (20)
Southern California (1557)
Tennessee (77)
Texas (603)
United States (15680)
Utah (131)
Virginia (88)
Washington D.C. (54)
Washington State (359)
West Virginia (3)
Wisconsin (36)
374,956 Results for "merck sharp and dohme".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg
Updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug secured approval for a type of kidney cancer in 2023.
June 2, 2025
·
2 min read
·
Nick Paul Taylor
RSV
Merck Wins FDA Nod for RSV Antibody, Tees Up Challenge to Sanofi, AstraZeneca
Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the third quarter.
June 10, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Merck Moves Forward in Bid To Bring First Oral PCSK9 Inhibitor to Market
Merck’s enlicitide decanoate significantly lowered low-density lipoprotein cholesterol in two Phase III trials, unlocking what BMO Capital Markets called a “multi-billion dollar opportunity” for the pharma.
June 9, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Action Alert: GSK, Sanofi, Merck and More
On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s oral cancer drug for a pair of rare tumors.
May 5, 2025
·
6 min read
·
Tristan Manalac
Cancer
Merck’s Injectable Keytruda Matches IV Formula in Pivotal Trial
Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay.
March 28, 2025
·
2 min read
·
Dan Samorodnitsky
Vaccines
Sales of Merck’s 4-Way Measles Vaccine Take Hit as US Dips Into Stockpile
Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks. Sales of the vaccine were $539 million for the quarter, a 5% decline from the same period in 2024.
April 24, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
aptaTargets transferred ApTOLL to Merck KGaA, Darmstadt, Germany
ApTOLL completed a Phase 1b/2 clinical trial for acute ischemic stroke with positive results. Merck KGaA, Darmstadt, Germany, to assume clinical development and commercialization of ApTOLL.
May 22, 2025
·
1 min read
Vaccines
Two of Kennedy’s New ACIP Picks Were Paid Expert Witnesses in Merck Vaccine Cases
Martin Kulldorff and Robert Malone, both outspoken vaccine skeptics, have received compensation for their expert participation in various vaccine-related cases against Merck.
June 13, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
Merck continues to build the case for the pulmonary arterial hypertension drug that won FDA approval in 2024.
April 1, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Merck KGaA Moves Ahead on SpringWorks Buy for $3.9B
The transaction is expected to close in the second half of 2025. With the deal, Merck KGaA is adding to its rare disease and oncology pipelines.
April 28, 2025
·
3 min read
·
Tristan Manalac
1 of 37,496
Next
